Format

Send to

Choose Destination
J Immunother Cancer. 2018 Mar 6;6(1):19. doi: 10.1186/s40425-018-0330-1.

Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses.

Author information

1
Hoag Cancer Institute, Newport Beach, CA, 92660, USA. robert.dillman55@gmail.com.
2
AIVITA Biomedical, Inc., Irvine, CA, USA. robert.dillman55@gmail.com.
3
TCR2 Therapeutics, Cambridge, MA, USA.
4
AIVITA Biomedical, Inc., Irvine, CA, USA.
5
California Cancer Associates for Research and Excellence (cCARE), Institute for Melanoma Research & Education, Encinitas, CA, USA.
6
Minnesota Oncology, Fridley, MN, USA.
7
, Franklin, TN, USA.

Abstract

BACKGROUND:

Despite improved survival following checkpoint inhibitors, there is still a potential role for anti-cancer therapeutic vaccines. Because of biological heterogeneity and neoantigens resulting from each patient's mutanome, autologous tumor may be the best source of tumor-associated antigens (TAA) for vaccines. Ex vivo loading of autologous dendritic cells with TAA may be associated with superior clinical outcome compared to injecting irradiated autologous tumor cells. We conducted a randomized phase II trial to compare autologous tumor cell vaccines (TCV) and autologous dendritic cell vaccines (DCV) loaded with autologous TAA.

METHODS:

Short-term autologous tumor cell lines were established from metastatic tumor. Vaccines were admixed with 500 micrograms of GM-CSF and injected weekly for 3 weeks, then at weeks 8, 12,16, 20, and 24. The primary endpoint was overall survival. Secondary objectives were identification of adverse events, and results of delayed type hypersensitivity (DTH) reactions to intradermal tumor cell injections.

RESULTS:

Forty-two patients were randomized. All were followed from randomization until death or for five years; none were lost to follow-up. DCV was associated with longer survival: median 43.4 versus 20.5 months (95% CI, 18.6 to > 60 versus 9.3 to 32.3 months) and a 70% reduction in the risk of death (hazard ratio = 0.304, p = 0.0053, 95% CI, 0.131 to 0.702). Tumor DTH reactions were neither prognostic nor predictive. The most common treatment-related adverse events were mild to moderate local injection site reactions and flu-like symptoms; but grade 2 treatment-related adverse events were more frequent with TCV. Serum marker analyses at week-0 and week-4 showed that serum markers were similar at baseline in each arm, but differed after vaccination.

CONCLUSIONS:

This is the only human clinical trial comparing DCV and TCV as platforms for autologous TAA presentation. DCV was associated with minimal toxicity and long-term survival in patients with metastatic melanoma. DTH to autologous tumor cells was neither prognostic for survival nor predictive of benefit for either vaccine.

TRIAL REGISTRATION:

Clinical trials.gov NCT00948480 retrospectively registered 28 July 2009.

KEYWORDS:

Autologous tumor cell lines; Dendritic-cell vaccines; Metastatic melanoma; Patient-specific vaccines; Tumor-cell vaccines

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center